© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
EGFR+ Lung Cancer
BLU-945 Shows Early Antitumor Activity in EGFR-Mutated NSCLC Models
September 20, 2020
In preclinical models of triple-mutated EGFR-positive non–small cell lung cancer, the investigational agent, BLU-945 induced robust antitumor responses, according to results presented at the 2020 European Society of Medical Oncology Virtual Congress.
Clinical Trials Excite Treatment Landscape for Early-Stage EGFR-Mutated NSCLC
September 18, 2020
Balazs Halmos, MD, MS, discusses 2 major presentations from the 2020 American Society of Clinical Oncology Virtual Scientific Program that appeared promising for the treatment of patients with EGFR-mutant non–small cell lung cancer.
Pennell Examines Targeted Therapies in EGFR-Mutated NSCLC
September 13, 2020
Nathan A. Pennell, MD, PhD, discussed the case of 66-year-old patient with EGFR-mutant non–small cell lung cancer, during a virtual Case Based Peer Perspectives event.
Osimertinib Shows No OS Benefit Versus Chemotherapy in EGFR T790M-Mutant Advanced NSCLC Study
September 03, 2020
A statistically significant overall survival benefit was not observed with osimertinib compared with platinum-pemetrexed therapy as treatment of patients with EGFR T790M-mutated advanced non–small cell lung cancer.
Real-World Study Expands Benefit-Risk Assessment Data for Osimertinib in EGFR+ NSCLC
September 03, 2020
The benefits and risks of osimertinib as second- or later-line treatment of patients with EGFR-positive non–small cell lung cancer that were reported when the agent was first approved, have now been confirmed, according to data from a real-world study conducted in Japan.
GioTag Update: Final OS Promising for Sequential Afatinib Following Osimertinib in EGFR+ NSCLC
September 02, 2020
Sequential afatinib followed by osimertinib led to encouraging outcomes in patients with deletion 19 (del19) or L858R epidermal growth factor receptor (EGFR)-mutant non–small cell lung cancer, according to the final analysis results from the real-world study, GioTag.
Clinical Cases in Lung Cancer
August 31, 2020
Experts in lung oncology review 3 clinical cases and discuss individualized treatment approaches for each patient.
Inferior Survival Outcomes Revealed in African American Patients with EGFR-Mutant NSCLC
August 27, 2020
This is the first report to date that has demonstrated inferior survival outcomes among African American patients with NSCLC harboring an EGFR mutation relative to non-African American patients.
Indications Continue to Expand for EGFR Targeted Therapies in Lung Cancer
August 14, 2020
Research into mutations in the gene encoding the epidermal growth factor receptor protein has revolutionized non–small cell lung cancer treatment in recent years, yet the science supporting targeting of this oncogene is still being elucidated.
NSCLC With EGFR Exon 20 Shows Benefit With Mobocertinib Over Chemotherapy
August 11, 2020
Leora Horn, MD, MSc, discusses the data accrued from Flatiron and from a phase 1/2 trial of patients with refractory non–small cell lung cancer with EGFR exon 20 insertions receiving mobocertinib compared with currently approved therapies.